# US 2021/0071264 A1 · Expression and genetic profiling for treatment and classification of dlbcl

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0071264 A1
- Document ID: US20210071264A1
- Status: Published application
- Kind: A1
- Application number: 17/018,347
- Filed: 2020-09-11
- Published: 2021-03-11
- Earliest claimed: 2019-09-11
- Assignees: Genomic Testing Cooperative, LCA
- Applicants: Genomic Testing Cooperative, LCA
- Inventors: Maher Albitar
- Web page: https://patentgrep.com/patent/US20210071264A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6827: for detection of mutation or polymorphism
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of treating diffuse large B-cell lymphoma, comprises obtaining a sample from a patient having diffuse large B-cell lymphoma; detecting in the sample, by an assay, mutation in each gene in a first panel; quantifying in the sample an expression level of each gene in a second panel; classifying the diffuse large B-cell lymphoma of the patient as having a cell of origin of either (i) germinal-center B-cell-like or (ii) activated B-cell-like; and treating the patient with a cancer treatment therapy regime. The first panel comprises at least one gene selected from the group consisting of EZH1 and MYD88; and the second panel comprises at least one gene selected from the group consisting of IRF4, MYBL1, RASGRF1, S1PR2 and SSBP2.

## Claims

### Claim 1

A method of treating diffuse large B-cell lymphoma, comprising:
obtaining a sample from a patient having diffuse large B-cell lymphoma;
detecting in the sample, by an assay, mutation in each gene in a first panel;
quantifying in the sample an expression level of each gene in a second panel;
classifying the diffuse large B-cell lymphoma of the patient as having a cell of origin of either (i) germinal-center B-cell-like or (ii) activated B-cell-like; and
treating the patient with a cancer treatment therapy regime;
wherein the first panel comprises at least one gene selected from the group consisting of EZH1 and MYD88; and
the second panel comprises at least one gene selected from the group consisting of IRF4, MYBL1, RASGRF1, S1PR2 and SSBP2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first panel comprises EZH1 and MYD88, and the second panel comprises IRF4, MYBL1, RASGRF1, S1PR2 and SSBP2.

### Claim 3 (depends on 1)

The method of claim 1, wherein first panel comprises EZH1 and MYD88, and the second panel comprises AFF3, AHR, AUTS2, BCAS4, BCL6, BTLA, CARD11, CCND2, CCND3, CD22, CD44, COL9A3, CREB3L2, EBF1, ETV6, FAM46C, FOXP1, IKZF1, IL2RA, IRF4, IRS1, KANK1, LCK, LMO2, LPP, LRMP, LRP5, LRRK2, LYL1, LYN, METTL7B, MYBL1, P2RY8, PAG1, PAK6, PDGFD, PIK3CG, PIM1, PTK2, PTK2B, PTPN2, RASGRF1, S1PR2, SSBP2, STAT3 and TBL1XR1.

### Claim 4 (depends on 1)

The method of claim 1, wherein the detecting in the sample mutation in each gene in the first panel, and quantifying in the sample the expression level of each gene in the second panel, is carried out by performing next generation sequencing in a single assay.

### Claim 5 (depends on 1)

The method of claim 1, wherein the treating of the patient with the cancer treatment therapy regime comprises administering at least one therapy selected from the group consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, obinutuzumab, dexamethasone, cytarabine, cisplatin, lenalidomide, ibrutinib, bortezomib, durvalumab and autologous stem cell transplantation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the confidence of classifying the diffuse large B-cell lymphoma of the patient as having the cell of origin of either (i) germinal-center B-cell-like or (ii) activated B-cell-like is a probability of at least 0.8.

### Claim 7

A method, comprising:
detecting in a sample from a patient having diffuse large B-cell lymphoma, by an assay, mutation in each gene in a first panel; and
quantifying in the sample an expression level of each gene in a second panel;
wherein the first panel comprises at least one gene selected from the group consisting of EZH1 and MYD88; and
the second panel comprises at least one gene selected from the group consisting of IRF4, MYBL1, RASGRF1, S1PR2 and SSBP2.

### Claim 8 (depends on 7)

The method of claim 7, wherein the first panel comprises EZH1 and MYD88, and the second panel comprises IRF4, MYBL1, RASGRF1, S1PR2 and SSBP2.

### Claim 9 (depends on 7)

The method of claim 7, wherein first panel comprises EZH1 and MYD88, and the second panel comprises AFF3, AHR, AUTS2, BCAS4, BCL6, BTLA, CARD11, CCND2, CCND3, CD22, CD44, COL9A3, CREB3L2, EBF1, ETV6, FAM46C, FOXP1, IKZF1, IL2RA, IRF4, IRS1, KANK1, LCK, LMO2, LPP, LRMP, LRP5, LRRK2, LYL1, LYN, METTL7B, MYBL1, P2RY8, PAG1, PAK6, PDGFD, PIK3CG, PIM1, PTK2, PTK2B, PTPN2, RASGRF1, S1PR2, SSBP2, STAT3 and TBL1XR1.

### Claim 10 (depends on 7)

The method of claim 7, wherein the detecting in the sample mutation in each gene in the first panel, and quantifying in the sample the expression level of each gene in the second panel, is carried out by performing next generation sequencing in a single assay.

### Claim 11 (depends on 7)

The method of claim 7, further comprising treating the patient with a cancer treatment therapy regime comprises administering at least one therapy selected from the group consisting of cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab, obinutuzumab, dexamethasone, cytarabine, cisplatin, lenalidomide, ibrutinib, bortezomib, durvalumab and autologous stem cell transplantation.

### Claim 12 (depends on 7)

The method of claim 7, wherein the sample is formaldehyde-fixed paraffin-embedded tissue.

### Claim 13

A method, comprising:
detecting in a sample from a patient having diffuse large B-cell lymphoma, by an assay, mutation in each gene in a first panel; and
quantifying in the sample an expression level of each gene in a second panel;
wherein the first panel comprises TP53; and
the second panel comprises at least one gene selected from the group consisting of CARD11, BCL6, MALAT1, RABEP1 and BCORL1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the second panel comprises CARD11, BCL6, MALAT1, RABEP1 and BCORL1.

### Claim 15 (depends on 13)

The method of claim 13, wherein the first panel comprises TP53 and TET2, and the second panel comprises AFF3, ASPSCR1, BCL2, BCL6, BCORL1, BHLHE22, BTK, CARD11, CCND2, CD58, CHEK2, CIT, CREB3L2, DST, ETS1, EYA2, FANCF, FZD6, GAS5, HMGA1, HOXA9, IRF4, KDM5C, KLK2, LFNG, LMO2, MACROD1, MALAT1, MEF2B/MEF2BNB-MEF2B, MFNG, MLLT4, MTCP1, MYC, PIM1, POLD1, PPP3CA, RABEP1, RAD51B, RBM6, RECQL4, RHBDF2, RLTPR, RTEL1-TNFRSF6B, SMAD3, SPTBN1, SRRM3, ST6GAL1, SULF1, SYP, TEAD2, TFAP2A, TGFBR3, U2AF2 and ZIC2.

### Claim 16 (depends on 13)

The method of claim 13, wherein the detecting in the sample mutation in each gene in the first panel, and quantifying in the sample the expression level of each gene in the second panel, is carried out by performing next generation sequencing in a single assay.

### Claim 17 (depends on 13)

The method of claim 13, wherein the sample is formaldehyde-fixed paraffin-embedded tissue.

### Claim 18

A method, comprising:
detecting in a sample from a patient having diffuse large B-cell lymphoma, by an assay, mutation in each gene in a first panel; and
quantifying in the sample an expression level of each gene in a second panel;
wherein the first panel comprises TP53; and
the second panel comprises at least one gene selected from the group consisting of CDK8, LMO2, BCR, TGFBR2, CHD2 and ETS1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the second panel comprises CDK8, LMO2, BCR, TGFBR2, CHD2 and ETS1.

### Claim 20 (depends on 18)

The method of claim 18, wherein the second panel comprises AFF1, AFF3, ASPSCR1, ATM, BCL2, BCR, BTG2, BTK, BTLA, CDK12, CDK8, CHD2, CHEK2, CIRH1A, CREB3L2, DDIT3, EDNRB, EPHB6, ETS1, FANCF, FOXP1, FZD6, GAB1, GAS5, GPR34, IQCG, ITGA7, KDM5C, KDSR, LAMA5, LFNG, LIFR, LMO2, MACROD1, MAP2K5, MFNG, MYC, NCSTN, NR6A1, POU2AF1, PRKCB, RLTPR, RPL22, SHC2, SMAD3, SPTBN1, ST6GAL1, TEAD2 and TGFBR2.

### Claim 21 (depends on 18)

The method of claim 18, wherein the detecting in the sample mutation in each gene in the first panel, and quantifying in the sample the expression level of each gene in the second panel, is carried out by performing next generation sequencing in a single assay.

### Claim 22 (depends on 18)

The method of claim 18, wherein the sample is formaldehyde-fixed paraffin-embedded tissue.
